Laboratory Head: Kazuhiro Yamakawa
The objective of our laboratory is to understand the molecular pathomechanisms of neurological diseases including epilepsy, autism, and mental retardation, and to develop diagnostic methods and therapies for those diseases. To do this, we are identifying and characterizing the genes responsible for those diseases by suing more than 4000 patients' materials, developing animal disease models, and testing therapeutic methodologies including gene therapy. The epilepsy project includes juvenile myoclonic epilepsy and sodium channelopathy such as generalized epilepsy with febrile seizures plus (GEFS+) and severe myoclonic epilepsy in infancy (SMEI) that associates with severe mental decline. We also analyzing cases with epilepsy associated with autism by using full genome analyses. The mental retardation project includes Down syndrome that is the most frequent mental retardation and is caused by trisomy 21. We are characterizing partial trisomy 16 mice as DS animal models, analyzing histological, immunohistochemical, biochemical, behavioral abnormalities and testing potential therapies.
The scenery of our lab.
Press Release, etc.